China’s Akeso, hailed as biotech’s ‘DeepSeek moment’, falls despite nod for cancer drug

INSUBCONTINENT EXCLUSIVE:

Chinese regulator grants second approval for lung cancer drug ivonescimab, which has outperformed Mercks Keytruda in phase three trial.